Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

BACKGROUND: Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor mutational burden (TMB) also being explored with pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Smith, Kellie N., Llosa, Nicolas J., Cottrell, Tricia R., Siegel, Nicholas, Fan, Hongni, Suri, Prerna, Chan, Hok Yee, Guo, Haidan, Oke, Teniola, Awan, Anas H., Verde, Franco, Danilova, Ludmila, Anagnostou, Valsamo, Tam, Ada J., Luber, Brandon S., Bartlett, Bjarne R., Aulakh, Laveet K., Sidhom, John-William, Zhu, Qingfeng, Sears, Cynthia L., Cope, Leslie, Sharfman, William H., Thompson, Elizabeth D., Riemer, Joanne, Marrone, Kristen A., Naidoo, Jarushka, Velculescu, Victor E., Forde, Patrick M., Vogelstein, Bert, Kinzler, Kenneth W., Papadopoulos, Nickolas, Durham, Jennifer N., Wang, Hao, Le, Dung T., Justesen, Sune, Taube, Janis M., Diaz, Luis A., Brahmer, Julie R., Pardoll, Drew M., Anders, Robert A., Housseau, Franck
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2019
Schlagworte:
Case Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6371497/
https://ncbi.nlm.nih.gov/pubmed/30744692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0492-x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge